Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen.

被引：0
|
作者：
Lipton, A
Leitzel, K
Ali, SM
Demers, L
Harvey, HA
Chaudri-Ross, HA
Lang, R
Hackl, W
Hamer, P
Carney, W
机构：
[1] Penn State Hershey Med Ctr, Lebanon VA Med Ctr, Hershey, PA USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Oncogene Sci Bayer Diagnost, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：288S / 288S
页数：1
相关论文
共 50 条
  • [41] Serum HER-2/neu has clinical utility in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzamab-based therapies
    Cheli, CQ
    Esteva, FJ
    Fritsche, H
    Fornier, M
    Slamon, D
    Thiel, RP
    Lueftner, D
    Ghani, F
    CLINICAL CHEMISTRY, 2005, 51 : A56 - A56
  • [42] Decrease in serum HER-2/neu levels at 4 to 16 weeks is associated with prolonged progression-free survival in metastatic breast cancer patients treated with lapatinib monotherapy
    Carney, W. P.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Platek, G.
    O'Rourke, L.
    Martin, A.
    Maltzman, J.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A157 - A157
  • [43] Patients with elevated serum HER-2/neu show increased response to Herceptin therapy in metastatic breast cancer.
    Schwartz, MK
    Ghani, F
    Dnistrian, AM
    Kish, L
    Schwartz, DC
    Armstrong, G
    CLINICAL CHEMISTRY, 2002, 48 (06) : A20 - A20
  • [44] Comparison of serum HER-2/neu levels and clinical response in metastatic breast cancer patients on Herceptin therapy.
    Kish, LA
    Goldblatt, J
    Neaman, I
    Levine, R
    Ghani, F
    Armstrong, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : A132 - A132
  • [45] Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay
    Dittadi, R
    Zancan, M
    Perasole, A
    Gion, M
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (04): : 255 - 261
  • [46] Monitoring Serum HER-2/neu levels in metastatic breast cancer patients undergoing herceptin therapy regimens.
    Carney, WP
    Brown-Shimer, S
    Lin, D
    Schwartz, MK
    CLINICAL CHEMISTRY, 2003, 49 (06) : A100 - A100
  • [47] Monitoring serum HER-2/neu levels in metastatic breast cancer patients undergoing Herceptin® therapy regimens.
    Brown-Shimer, SL
    Schwartz, MK
    Schwartz, D
    Lin, D
    Carney, WP
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S111 - S111
  • [48] Comparison of serum and tissue HER-2/neu expression in metastatic breast cancer patients prior to Herceptin therapy.
    Kish, LA
    Goldblatt, J
    Neaman, I
    Kaplan, IV
    Lin, D
    Schwartz, D
    Ghani, F
    Armstrong, G
    Schwartz, KM
    CLINICAL CHEMISTRY, 2001, 47 (06) : A132 - A132
  • [49] The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer
    Carney, WP
    LABORATORY MEDICINE, 2003, 34 (01) : 58 - 64
  • [50] Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
    Köstler, WJ
    Schwab, B
    Singer, CF
    Neumann, R
    Rücklinger, E
    Brodowicz, T
    Tomek, S
    Niedermayr, M
    Hejna, M
    Steger, GG
    Krainer, M
    Wiltschke, C
    Zielinski, CC
    CLINICAL CANCER RESEARCH, 2004, 10 (05) : 1618 - 1624
12345